

Gene therapy of metachromatic leukodystrophy reverses in mice

Journal of Clinical Investigation

116, 3070-3082

DOI: [10.1172/jci28873](https://doi.org/10.1172/jci28873)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Novel candidate disease for gene therapy: metachromatic leukodystrophy. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1193-1205.	1.4	9
2	SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies. <i>Biochemical Journal</i> , 2007, 403, 305-312.	1.7	69
3	Safety of Arylsulfatase A Overexpression for Gene Therapy of Metachromatic Leukodystrophy. <i>Human Gene Therapy</i> , 2007, 18, 821-836.	1.4	47
4	MR-based imaging of neural stem cells. <i>Neuroradiology</i> , 2007, 49, 523-534.	1.1	42
6	Enzyme, cell and gene-based therapies for metachromatic leukodystrophy. <i>Journal of Inherited Metabolic Disease</i> , 2007, 30, 175-183.	1.7	72
7	The Role and Metabolism of Sulfatide in the Nervous System. <i>Molecular Neurobiology</i> , 2008, 37, 93-103.	1.9	166
8	Co-expression of MGMT ^{P140K} and β -glucuronidase in primary hepatocytes from mucopolysaccharidosis type I mice enables efficient selection with metabolic correction. <i>Journal of Gene Medicine</i> , 2008, 10, 249-259.	1.4	9
9	Cell-based drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 286-295.	6.6	235
10	Metachromatic leukodystrophy: an overview of current and prospective treatments. <i>Bone Marrow Transplantation</i> , 2008, 42, S2-S6.	1.3	97
11	Gene therapy approaches for stem cell protection. <i>Gene Therapy</i> , 2008, 15, 100-108.	2.3	26
12	Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic options. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2008, 97, 15-21.	0.7	117
13	From bone marrow to microglia: barriers and avenues. <i>Trends in Immunology</i> , 2008, 29, 227-234.	2.9	147
14	Gazing into the future: Parkinson's disease gene therapeutics to modify natural history. <i>Experimental Neurology</i> , 2008, 209, 101-113.	2.0	9
15	Early signs of neurolipidosis-related behavioural alterations in a murine model of metachromatic leukodystrophy. <i>Behavioural Brain Research</i> , 2008, 189, 306-316.	1.2	21
16	Patented therapeutic RNAi strategies for neurodegenerative diseases of the CNS. <i>Expert Opinion on Therapeutic Patents</i> , 2008, 18, 1161-1174.	2.4	6
17	Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. <i>Neurology</i> , 2008, 71, 1326-1334.	1.5	123
19	Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders. <i>Current Gene Therapy</i> , 2008, 8, 461-473.	0.9	139
20	Specific Determination of β -Galactocerebrosidase Activity via Competitive Inhibition of β -Galactosidase. <i>Clinical Chemistry</i> , 2009, 55, 541-548.	1.5	43

#	ARTICLE	IF	CITATIONS
21	Enzyme Replacement Improves Ataxic Gait and Central Nervous System Histopathology in a Mouse Model of Metachromatic Leukodystrophy. <i>Molecular Therapy</i> , 2009, 17, 600-606.	3.7	64
22	Dlg1, Sec8, and Mtmr2 Regulate Membrane Homeostasis in Schwann Cell Myelination. <i>Journal of Neuroscience</i> , 2009, 29, 8858-8870.	1.7	101
23	Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 19958-19963.	3.3	49
24	Therapy for lysosomal storage disorders. <i>IUBMB Life</i> , 2010, 62, 33-40.	1.5	72
25	Global diffuse distribution in the brain and efficient gene delivery to the dorsal root ganglia by intrathecal injection of adeno-associated viral vector serotype 1. <i>Journal of Gene Medicine</i> , 2009, 11, 498-505.	1.4	30
26	Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy. <i>Science</i> , 2009, 326, 818-823.	6.0	1,368
27	Leukodystrophies. <i>Neurologist</i> , 2009, 15, 319-328.	0.4	82
28	Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype. <i>Blood</i> , 2010, 115, 5329-5337.	0.6	81
29	The galactocerebrosidase enzyme contributes to the maintenance of a functional hematopoietic stem cell niche. <i>Blood</i> , 2010, 116, 1857-1866.	0.6	50
30	Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. <i>Blood</i> , 2010, 116, 5130-5139.	0.6	159
31	Identification of Hematopoietic Stem Cell-Specific miRNAs Enables Gene Therapy of Globoid Cell Leukodystrophy. <i>Science Translational Medicine</i> , 2010, 2, 58ra84.	5.8	180
32	Multi-system disorders of glycosphingolipid and ganglioside metabolism. <i>Journal of Lipid Research</i> , 2010, 51, 1643-1675.	2.0	133
33	Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. <i>Human Molecular Genetics</i> , 2010, 19, 147-158.	1.4	67
34	Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy. <i>Neurology</i> , 2010, 75, 1896-1903.	1.5	37
35	Successful Treatment of Metachromatic Leukodystrophy Using Bone Marrow Transplantation of HoxB4 Overexpressing Cells. <i>Molecular Therapy</i> , 2010, 18, 1373-1378.	3.7	23
36	Recent Advances in Lentiviral Vector Development and Applications. <i>Molecular Therapy</i> , 2010, 18, 477-490.	3.7	288
37	Clinical and biochemical study of 29 Brazilian patients with metachromatic leukodystrophy. <i>Journal of Inherited Metabolic Disease</i> , 2010, 33, 257-262.	1.7	18
38	Macrophage-mediated GDNF Delivery Protects Against Dopaminergic Neurodegeneration: A Therapeutic Strategy for Parkinson's Disease. <i>Molecular Therapy</i> , 2010, 18, 1536-1544.	3.7	91

#	ARTICLE	IF	CITATIONS
39	Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice. <i>Experimental Neurology</i> , 2010, 225, 445-454.	2.0	30
40	Myelin lesions associated with lysosomal and peroxisomal disorders. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1449-1466.	1.4	30
41	Magslectofection: an integrated method of nanomagnetic separation and genetic modification of target cells. <i>Blood</i> , 2011, 117, e171-e181.	0.6	40
42	Magnetic Resonance Imaging Tracking of Stem Cells in Vivo Using Iron Oxide Nanoparticles as a Tool for the Advancement of Clinical Regenerative Medicine. <i>Chemical Reviews</i> , 2011, 111, 253-280.	23.0	385
43	Telencephalic histopathology and changes in behavioural and neural plasticity in a murine model for metachromatic leukodystrophy. <i>Behavioural Brain Research</i> , 2011, 222, 309-314.	1.2	3
44	Unrelated umbilical cord blood transplant for juvenile metachromatic leukodystrophy: A 5-year follow-up in three affected siblings. <i>Molecular Genetics and Metabolism</i> , 2011, 102, 207-209.	0.5	20
45	Gene therapy for leukodystrophies. <i>Human Molecular Genetics</i> , 2011, 20, R42-R53.	1.4	83
46	Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. <i>Blood</i> , 2011, 117, 5332-5339.	0.6	201
47	Ex vivo gene transfer and correction for cell-based therapies. <i>Nature Reviews Genetics</i> , 2011, 12, 301-315.	7.7	340
48	A bidirectional promoter architecture enhances lentiviral transgenesis in embryonic and extraembryonic stem cells. <i>Gene Therapy</i> , 2011, 18, 817-826.	2.3	14
50	The Myelin Mutants as Models to Study Myelin Repair in the Leukodystrophies. <i>Neurotherapeutics</i> , 2011, 8, 607-624.	2.1	37
51	Genetic therapy for the nervous system. <i>Human Molecular Genetics</i> , 2011, 20, R28-R41.	1.4	62
52	Lysosomal Lipid Storage Diseases. <i>Cold Spring Harbor Perspectives in Biology</i> , 2011, 3, a004804-a004804.	2.3	142
53	Stem Cell Transplantation in Inherited Metabolic Disorders. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 285-291.	0.9	38
54	Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 15018-15023.	3.3	168
55	Hematopoietic Stem Cell and Gene Therapy Corrects Primary Neuropathology and Behavior in Mucopolysaccharidosis IIIA Mice. <i>Molecular Therapy</i> , 2012, 20, 1610-1621.	3.7	94
56	Correction of Brain Oligodendrocytes by AAVrh.10 Intracerebral Gene Therapy in Metachromatic Leukodystrophy Mice. <i>Human Gene Therapy</i> , 2012, 23, 903-914.	1.4	73
57	Ex Vivo Gene Therapy and Vision. <i>Current Gene Therapy</i> , 2012, 12, 103-115.	0.9	18

#	ARTICLE	IF	CITATIONS
58	Correction of Pathological Accumulation of Glycosaminoglycans in Central Nervous System and Peripheral Tissues of MPSIIIA Mice Through Systemic AAV9 Gene Transfer. <i>Human Gene Therapy</i> , 2012, 23, 1237-1246.	1.4	102
59	Developing treatment options for metachromatic leukodystrophy. <i>Molecular Genetics and Metabolism</i> , 2012, 105, 56-63.	0.5	41
60	Lipid peptide nanocomplexes for gene delivery and magnetic resonance imaging in the brain. <i>Journal of Controlled Release</i> , 2012, 162, 340-348.	4.8	32
61	Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2012, 101, 692-701.	0.7	16
62	Gene therapy for disorders of the central nervous system. <i>Handbook of Clinical Neurology / Edited By PJ Vinken and G W Bruyn</i> , 2013, 113, 1859-1866.	1.0	4
63	Spingolipid Disorders and the Neuronal Ceroid Lipofuscinoses or Batten Disease (Wolman Disease,) Tj ETQq1 1 0.784314 rgBT /Overdo		
64	Myeloid/Microglial Driven Autologous Hematopoietic Stem Cell Gene Therapy Corrects a Neuronopathic Lysosomal Disease. <i>Molecular Therapy</i> , 2013, 21, 1938-1949.	3.7	96
65	Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy. <i>Science</i> , 2013, 341, 1233-1238.	6.0	998
66	The final frontier "crossing the blood-brain barrier. <i>EMBO Molecular Medicine</i> , 2013, 5, 655-657.	3.3	10
67	Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice. <i>Gene Therapy</i> , 2013, 20, 913-921.	2.3	33
68	Toward a gene therapy for neurological and somatic MPSIIIA. <i>Rare Diseases (Austin, Tex)</i> , 2013, 1, e27209.	1.8	7
69	Therapy for Neuronopathic Lysosomal Storage Diseases. , 2013, , 243-258.		0
70	Advances and Pitfalls of Cell Therapy in Metabolic Leukodystrophies. <i>Cell Transplantation</i> , 2013, 22, 189-204.	1.2	17
71	Developing therapeutic approaches for metachromatic leukodystrophy. <i>Drug Design, Development and Therapy</i> , 2013, 7, 729.	2.0	42
72	Comparative Efficacy and Safety of Multiple Routes of Direct CNS Administration of Adeno-Associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human Arylsulfatase A cDNA to Nonhuman Primates. <i>Human Gene Therapy Clinical Development</i> , 2014, 25, 164-177.	3.2	46
73	Lentivector Integration Sites in Ependymal Cells From a Model of Metachromatic Leukodystrophy: Non-B DNA as a New Factor Influencing Integration. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e187.	2.3	13
74	Clinical Applications Involving CNS Gene Transfer. <i>Advances in Genetics</i> , 2014, 87, 71-124.	0.8	54
75	Long-term correction of biochemical and neurological abnormalities in MLD mice model by neonatal systemic injection of an AAV serotype 9 vector. <i>Gene Therapy</i> , 2014, 21, 427-433.	2.3	32

#	ARTICLE	IF	CITATIONS
76	Metallothioneins as dynamic markers for brain disease in lysosomal disorders. <i>Annals of Neurology</i> , 2014, 75, 127-137.	2.8	17
77	Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease. <i>European Journal of Neuroscience</i> , 2014, 39, 2139-2150.	1.2	16
78	Sphingolipids and lysosomal pathologies. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2014, 1841, 799-810.	1.2	88
79	A New Analytical Bench Assay for the Determination of Arylsulfatase A Activity Toward Galactosyl-3-Sulfate Ceramide: Implication for Metachromatic Leukodystrophy Diagnosis. <i>Analytical Chemistry</i> , 2014, 86, 473-481.	3.2	15
80	Gene therapy for the neurological manifestations in lysosomal storage disorders. <i>Journal of Lipid Research</i> , 2014, 55, 1827-1838.	2.0	22
81	New Innovations: Therapies for Genetic Conditions. <i>Current Genetic Medicine Reports</i> , 2014, 2, 113-123.	1.9	1
83	Sulfatide levels correlate with severity of neuropathy in metachromatic leukodystrophy. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 518-533.	1.7	34
84	Recent advances in gene therapy for lysosomal storage disorders. <i>The Application of Clinical Genetics</i> , 2015, 8, 157.	1.4	36
85	Design of a regulated lentiviral vector for hematopoietic stem cell gene therapy of globoid cell leukodystrophy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 15038.	1.8	29
86	Shedding of clinical-grade lentiviral vectors is not detected in a gene therapy setting. <i>Gene Therapy</i> , 2015, 22, 496-502.	2.3	12
87	Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological symptoms in a murine model of globoid cell leukodystrophy. <i>Human Molecular Genetics</i> , 2015, 24, 3372-3389.	1.4	63
88	Gene Therapy for Rare Central Nervous System Diseases Comes to Age. <i>Endocrine Development</i> , 2016, 30, 141-146.	1.3	9
89	Innovative Treatments for Lysosomal Diseases. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2015, 29, 275-311.	2.2	24
90	Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II. <i>Human Gene Therapy</i> , 2015, 26, 357-366.	1.4	47
91	Lysosomal storage disease: Gene therapy on both sides of the blood-brain barrier. <i>Molecular Genetics and Metabolism</i> , 2015, 114, 83-93.	0.5	45
92	Arylsulfatase A Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy. <i>Molecular Therapy</i> , 2015, 23, 1519-1531.	3.7	44
93	Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates. <i>Human Gene Therapy Clinical Development</i> , 2015, 26, 113-124.	3.2	68
94	Gene therapy returns to centre stage. <i>Nature</i> , 2015, 526, 351-360.	13.7	943

#	ARTICLE	IF	CITATIONS
95	Hematopoietic stem cell transplantation for metachromatic leukodystrophy. Expert Opinion on Orphan Drugs, 2015, 3, 911-919.	0.5	4
96	Rapid and Efficient Stable Gene Transfer to Mesenchymal Stromal Cells Using a Modified Foamy Virus Vector. Molecular Therapy, 2016, 24, 1227-1236.	3.7	10
97	Lentiviral Vector-Mediated Correction of a Mouse Model of Leukocyte Adhesion Deficiency Type I. Human Gene Therapy, 2016, 27, 668-678.	1.4	21
98	Alterations in membrane trafficking and pathophysiological implications in lysosomal storage disorders. Biochimie, 2016, 130, 152-162.	1.3	29
100	Preclinical Testing of the Safety and Tolerability of Lentiviral Vector-Mediated Above-Normal Alpha-L-Iduronidase Expression in Murine and Human Hematopoietic Cells Using Toxicology and Biodistribution Good Laboratory Practice Studies. Human Gene Therapy, 2016, 27, 813-829.	1.4	40
101	Gene therapy for metachromatic leukodystrophy. Journal of Neuroscience Research, 2016, 94, 1169-1179.	1.3	64
102	Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet, The, 2016, 388, 476-487.	6.3	393
103	Engineering Stem Cells for Biomedical Applications. Advanced Healthcare Materials, 2016, 5, 10-55.	3.9	25
104	Gene therapy for leukodystrophy: progress, challenges and opportunities. Expert Opinion on Orphan Drugs, 2016, 4, 359-367.	0.5	8
105	Modulators of microglia: a patent review. Expert Opinion on Therapeutic Patents, 2016, 26, 427-437.	2.4	23
106	Gene therapy for lysosomal storage disorders: a good start. Human Molecular Genetics, 2016, 25, R65-R75.	1.4	44
107	Outcome of Early Juvenile Onset Metachromatic Leukodystrophy After Unrelated Cord Blood Transplantation: A Case Series and Review of the Literature. Journal of Child Neurology, 2016, 31, 338-344.	0.7	18
108	Bone marrow-derived macrophages and the CNS: An update on the use of experimental chimeric mouse models and bone marrow transplantation in neurological disorders. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 310-322.	1.8	43
109	Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID. Human Molecular Genetics, 2017, 26, 1535-1551.	1.4	39
110	Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications. Molecular Therapy, 2017, 25, 1155-1162.	3.7	68
111	Clinical Gene Therapy for Neurodegenerative Diseases: Past, Present, and Future. Human Gene Therapy, 2017, 28, 988-1003.	1.4	82
112	Intracerebroventricular delivery of hematopoietic progenitors results in rapid and robust engraftment of microglia-like cells. Science Advances, 2017, 3, e1701211.	4.7	38
113	Current and Future Treatments for Lysosomal Storage Disorders. Current Treatment Options in Neurology, 2017, 19, 45.	0.7	9

#	ARTICLE	IF	CITATIONS
114	Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccharidosis I. <i>Journal of Inherited Metabolic Disease</i> , 2017, 40, 543-554.	1.7	67
115	Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches. <i>Italian Journal of Pediatrics</i> , 2018, 44, 130.	1.0	38
116	Nonclinical comparability studies of recombinant human arylsulfatase A addressing manufacturing process changes. <i>PLoS ONE</i> , 2018, 13, e0195186.	1.1	8
117	Gene-Based Approaches to Inherited Neurometabolic Diseases. <i>Human Gene Therapy</i> , 2019, 30, 1222-1235.	1.4	28
118	Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 240.	1.2	54
119	Advances in the treatment of neuronal ceroid lipofuscinosis. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 473-500.	0.5	20
120	Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives. <i>EMBO Molecular Medicine</i> , 2019, 11, .	3.3	86
121	Autologous, Gene-Modified Hematopoietic Stem and Progenitor Cells Repopulate the Central Nervous System with Distinct Clonal Variants. <i>Stem Cell Reports</i> , 2019, 13, 91-104.	2.3	10
122	Assessing the Impact of Cyclosporin A on Lentiviral Transduction and Preservation of Human Hematopoietic Stem Cells in Clinically Relevant Ex Vivo Gene Therapy Settings. <i>Human Gene Therapy</i> , 2019, 30, 1133-1146.	1.4	8
123	Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 447-462.	21.5	141
124	Lysosomal Leukodystrophies Lysosomal Storage Diseases Associated With White Matter Abnormalities. <i>Journal of Child Neurology</i> , 2019, 34, 339-358.	0.7	14
125	Long-Term Persistence of Anti-HIV Broadly Neutralizing Antibody-Secreting Hematopoietic Cells in Humanized Mice. <i>Molecular Therapy</i> , 2019, 27, 164-177.	3.7	25
126	The influence of environment and origin on brain resident macrophages and implications for therapy. <i>Nature Neuroscience</i> , 2020, 23, 157-166.	7.1	74
127	Metabolism of Glycosphingolipids and Their Role in the Pathophysiology of Lysosomal Storage Disorders. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6881.	1.8	34
128	Lentiviral Hematopoietic Stem Cell Gene Therapy Rescues Clinical Phenotypes in a Murine Model of Pompe Disease. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 558-570.	1.8	11
129	In vitro Validation of Chimeric β -Galactosylceramidase Enzymes With Improved Enzymatic Activity and Increased Secretion. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 167.	1.6	6
130	Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches. <i>Frontiers in Medicine</i> , 2020, 7, 576221.	1.2	56
131	Gene therapy approaches in central nervous system regenerative medicine. , 2020, , 375-398.		0

#	ARTICLE	IF	CITATIONS
132	The Role of Hematopoietic Cell Transplant in the Glycoprotein Diseases. <i>Cells</i> , 2020, 9, 1411.	1.8	14
133	Experimental gene therapies for the NCLs. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165772.	1.8	11
134	Chinese Cases of Metachromatic Leukodystrophy with the Novel Missense Mutations in ARSA Gene. <i>Journal of Molecular Neuroscience</i> , 2021, 71, 245-251.	1.1	2
135	Update on Clinical Ex Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases. <i>Molecular Therapy</i> , 2021, 29, 489-504.	3.7	46
136	Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development. <i>Biomolecules</i> , 2021, 11, 611.	1.8	27
137	Canavan Disease as a Model for Gene Therapy-Mediated Myelin Repair. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 661928.	1.8	11
138	Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells. <i>Human Molecular Genetics</i> , 2021, 30, 1067-1083.	1.4	25
139	The transformative potential of HSC gene therapy as a genetic medicine. <i>Gene Therapy</i> , 2023, 30, 197-215.	2.3	13
140	Safety of Direct Intraparenchymal AAVrh.10-Mediated Central Nervous System Gene Therapy for Metachromatic Leukodystrophy. <i>Human Gene Therapy</i> , 2021, 32, 563-580.	1.4	18
141	Clinical Trials for Gene Therapy in Lysosomal Diseases With CNS Involvement. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 624988.	1.6	21
143	Hematopoietic Stem Cell Gene Therapy for Lysosomal Storage Disorders: Expected Benefits and Limitations. <i>Pancreatic Islet Biology</i> , 2013, , 127-138.	0.1	1
144	Transplantation of Oligodendrocyte Progenitor Cells in Animal Models of Leukodystrophies. <i>Methods in Molecular Biology</i> , 2009, 549, 175-185.	0.4	6
145	Microglia: a cellular vehicle for CNS gene therapy. <i>Journal of Clinical Investigation</i> , 2006, 116, 2857-2860.	3.9	33
146	Gene therapy for severe combined immunodeficiency: are we there yet?. <i>Journal of Clinical Investigation</i> , 2007, 117, 1456-1465.	3.9	196
147	Gene Therapy Corrects Mitochondrial Dysfunction in Hematopoietic Progenitor Cells and Fibroblasts from Coq9R239X Mice. <i>PLoS ONE</i> , 2016, 11, e0158344.	1.1	2
148	Treatment for Lysosomal Storage Disorders. <i>Current Pharmaceutical Design</i> , 2020, 26, 5110-5118.	0.9	12
149	Endocytic mechanisms and drug discovery in neurodegenerative diseases. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 6086.	3.0	7
150	Stem Cell Research Tools in Human Metabolic Disorders: An Overview. <i>Cells</i> , 2021, 10, 2681.	1.8	5

#	ARTICLE	IF	CITATIONS
152	General Forensic Neuropathology of Infants and Children. , 2008, , 247-341.		0
153	Leukodystrophies and Lysosomal Storage Disorders. Pancreatic Islet Biology, 2013, , 63-125.	0.1	2
155	Molecular Therapy for Lysosomal Storage Diseases. , 0, , .		0
156	Mitochondrial neurogastrointestinal encephalomyopathy syndrome: case report. BalÄ±kesir SaÄ±lÄ±k Bilimleri Dergisi, 2014, 3, 114-117.	0.0	0
157	General Forensic Neuropathology of Infants and Children. , 2014, , 263-362.		0
158	Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases and Its Implications for Future Gene Therapy Trials in Turke. Trakya University Journal of Natural Sciences, 0, , .	0.4	0
160	Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges. Advances in Experimental Medicine and Biology, 2021, , 135-162.	0.8	3
161	Gene Therapy Developments for Pompe Disease. Biomedicines, 2022, 10, 302.	1.4	19
162	Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. Lancet, The, 2022, 399, 372-383.	6.3	109
163	A Mutation-Agnostic Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy. CRISPR Journal, 2022, 5, 66-79.	1.4	8
165	Delineating the Neuropathology of Lysosomal Storage Diseases Using Patient-Derived Induced Pluripotent Stem Cells. Stem Cells and Development, 2022, 31, 221-238.	1.1	2
169	Genetic Manipulation of Hematopoietic Stem Cells. , 0, , 116-128.		0
170	Hematopoietic stem cell gene therapy ameliorates CNS involvement in murine model of GM1-gangliosidosis. Molecular Therapy - Methods and Clinical Development, 2022, 25, 448-460.	1.8	4
171	Haematopoietic stem cell gene therapy in inborn errors of metabolism. British Journal of Haematology, 2022, 198, 227-243.	1.2	5
172	New Indications for Hematopoietic Stem Cell Gene Therapy in Lysosomal Storage Disorders. Frontiers in Oncology, 2022, 12, .	1.3	6
173	High-throughput analysis of hematopoietic stem cell engraftment after intravenous and intracerebroventricular dosing. Molecular Therapy, 2022, 30, 3209-3225.	3.7	4
174	Gene Therapy for Pediatric Neurologic Disease. Hematology/Oncology Clinics of North America, 2022, , .	0.9	0
175	Genetically modified macrophages accelerate myelin repair. EMBO Molecular Medicine, 2022, 14, .	3.3	9

#	ARTICLE	IF	CITATIONS
176	Mammalian Sulfatases: Biochemistry, Disease Manifestation, and Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8153.	1.8	6
177	The therapeutic potential of bone marrow-derived macrophages in neurological diseases. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 1942-1952.	1.9	8
178	Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more, the merrier?. <i>Brain</i> , 2022, 145, 4178-4192.	3.7	15
179	Screening chimeric GAA variants in preclinical study results in hematopoietic stem cell gene therapy candidate vectors for Pompe disease. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 27, 464-487.	1.8	4
180	Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier. <i>Molecular Therapy</i> , 2023, 31, 657-675.	3.7	2
181	Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders. <i>Frontiers in Genome Editing</i> , 0, 4, .	2.7	2
182	Preserving Ambulation in a Gene Therapy-Treated Girl Affected by Metachromatic Leukodystrophy: A Case Report. <i>Journal of Personalized Medicine</i> , 2023, 13, 637.	1.1	1
183	Gene Therapy of Sphingolipid Metabolic Disorders. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3627.	1.8	6
184	New therapeutic strategies for the treatment of metachromatic leukodystrophy. <i>Genes and Cells</i> , 2020, 15, 41-50.	0.2	1
185	An innovative hematopoietic stem cell gene therapy approach benefits <i>CLN1</i> disease in the mouse model. <i>EMBO Molecular Medicine</i> , 2023, 15, .	3.3	3
186	<i>Ex vivo</i> gene therapy for lysosomal storage disorders: future perspectives. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 353-364.	1.4	1
187	Single Systemic Administration of a Gene Therapy Leading to Disease Treatment in Metachromatic Leukodystrophy <i>Arsa</i> Knock-Out Mice. <i>Journal of Neuroscience</i> , 2023, 43, 3567-3581.	1.7	1
188	Advances in therapies for neurological lysosomal storage disorders. <i>Journal of Inherited Metabolic Disease</i> , 2023, 46, 874-905.	1.7	10